Prognostic Modeling and Clinical Evaluation of Adverse Factors in Postherpetic Neuralgia Treated With Botulinum Toxin Type A: A Randomized Controlled Trial
BTX-A may offer benefit in relieving pain and reducing inflammation in PHN patients compared with standard treatment, and IL-6 may be a strong predictor of efficacy.
Authors
- Mingfu Zheng (ORCID: https://orcid.org/0000-0001-6822-6215)
- Li Ma (ORCID: https://orcid.org/0000-0003-0083-8578)
- Lanrui Zeng
Institutions
- Gansu University of Traditional Chinese Medicine (CN)
- Gansu Provincial Hospital (CN)
- First Hospital of Lanzhou University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Clinical Neuropharmacology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1097/wnf.0000000000000654
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00